Bevacizumab-induced regression of anaplastic meningioma

Ann Oncol. 2010 Dec;21(12):2445-2446. doi: 10.1093/annonc/mdq634. Epub 2010 Nov 1.

Authors

M J A Puchner, V H Hans¹, A Harati², F Lohmann², M Glas³, U Herrlinger⁴

Affiliations

¹ Institute of Neuropathology, Evangelisches Krankenhaus Bielefeld, Bielefeld.
² Department of Neurosurgery, Klinikum Vest GmbH-Knappschaftskrankenhaus Recklinghausen, Recklinghausen.
³ Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
⁴ Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany. Electronic address: [email protected].

PMID: 21041375
DOI: 10.1093/annonc/mdq634

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use
Bevacizumab
Female
Humans
Meningeal Neoplasms / drug therapy*
Meningioma / drug therapy*
Middle Aged
Remission Induction / methods
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab